Top

Published in:

Open Access 01-12-2018 | Review

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

Authors: Francesco Soria, Michael J. Droller, Yair Lotan, Paolo Gontero, David D’Andrea, Kilian M. Gust, Morgan Rouprêt, Marek Babjuk, Joan Palou, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 12/2018

Abstract

Objectives

With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette–Guerin (BCG) therapy.

Methods and materials

A medline/pubmed© literature search was performed. The performance of commercially available and investigational biomarkers has been reviewed. End points were cancer detection (recurrence), cancer progression, and response to BCG therapy.

Results

The performance requirements for biomarkers are variable according to the clinical scenario. The clinical role of urinary biomarkers in the follow-up of non-muscle invasive BCa patients remains undefined. The FDA-approved tests provide unsatisfactory sensitivity and specificity levels and their use is limited. Fluorescence in situ hybridization (FISH) has been shown to be useful in specific scenarios, mostly as a reflex test and in the setting of equivocal urinary cytology. FISH and immunocytology could conceivably be used to assess BCG response. Recently developed biomarkers have shown promising results; upcoming large trials will test their utility in specific clinical scenarios in a manner similar to a phased drug development strategy.

Conclusions

Current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice. Several novel biomarkers are currently under investigation. Prospective multicenter analyses will be needed to establish their clinical relevance and value.

Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European union. Eur Urol 69:438–447. https://doi.org/10.1016/j.eururo.2015.10.024 CrossRefPubMed

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295–300. https://doi.org/10.1007/s00345-009-0395-z CrossRefPubMedPubMedCentral

Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM et al (2016) EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update. Eur Urol 71:447–461. https://doi.org/10.1016/j.eururo.2016.05.041 (n.d.) CrossRefPubMed

Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N et al (2013) ICUD–EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63:4–15. https://doi.org/10.1016/j.eururo.2012.09.057 CrossRefPubMed

Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701–705. https://doi.org/10.1111/j.1464-410X.2010.09899.x CrossRefPubMed

Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M et al (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97:997–1001. https://doi.org/10.1111/j.1464-410X.2006.06036.x CrossRefPubMed

Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C et al (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol Semin Orig Investig 35:531.e15–531.e22. https://doi.org/10.1016/j.urolonc.2017.03.008 CrossRef

Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M et al (2017) Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate (HAL) in the surveillance of bladder cancer: a Phase III, comparative. Multi Center Study J Urol. https://doi.org/10.1016/j.juro.2017.11.096 CrossRef

Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484–492. https://doi.org/10.1016/j.eururo.2011.05.053 CrossRefPubMed

10.

Lawrentschuk N (2018) Evolution of technologies in urology: full steam ahead? World J Urol 36:517–518. https://doi.org/10.1007/s00345-018-2246-2 CrossRefPubMed

11.

Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ et al (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28:389–400. https://doi.org/10.1016/j.urolonc.2010.02.011 CrossRefPubMedPubMedCentral

12.

Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601–1609. https://doi.org/10.1016/j.eururo.2007.09.036 CrossRefPubMed

13.

Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448. https://doi.org/10.1016/j.urolonc.2009.11.004 CrossRefPubMed

14.

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196:1021–1029. https://doi.org/10.1016/j.juro.2016.06.049 CrossRef

15.

Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I et al (2015) Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol 33:1309–1313. https://doi.org/10.1007/s00345-014-1452-9 CrossRefPubMed

16.

Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat SF (2016) Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am 43:47–62. https://doi.org/10.1016/j.ucl.2015.08.005 CrossRefPubMed

17.

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T et al (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (Rockv) 14:1–331. https://doi.org/10.3310/hta14040 (iii–iv) CrossRef

18.

Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol Semin Orig Investig 33:66.e25–66.e31. https://doi.org/10.1016/j.urolonc.2014.06.008 CrossRef

19.

Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S et al (2016) Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol 34:1405–1409. https://doi.org/10.1007/s00345-016-1795-5 CrossRefPubMed

20.

Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I (2017) Urinary UBC Rapid and NMP22 Test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study. Int J Med Sci 14:811–819. https://doi.org/10.7150/ijms.19929 CrossRefPubMedPubMedCentral

21.

Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK et al (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117:2892–2897. https://doi.org/10.1002/cncr.25903 CrossRefPubMedPubMedCentral

22.

Shariat SF, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R et al (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173:1518–1525. https://doi.org/10.1097/01.ju.0000154696.48217.75 CrossRefPubMed

23.

Babjuk M, Soukup V, Pešl M, Koštířová M, Drncová E, Smolová H et al (2008) Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71:718–722. https://doi.org/10.1016/j.urology.2007.12.021 CrossRefPubMed

24.

Raitanen M-P (2008) FinnBladder group. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26:45–50. https://doi.org/10.1007/s00345-007-0230-3 CrossRefPubMed

25.

Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC et al (2002) Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95:61–72. https://doi.org/10.1002/cncr.10652 CrossRefPubMed

26.

Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF et al (1995) Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154:379–383 (discussion 383-4) CrossRefPubMed

27.

Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J et al (2012) Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61:185–192. https://doi.org/10.1016/j.eururo.2011.08.073 CrossRefPubMed

28.

Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L et al (2006) uCyt +/ImmunoCyt™ in the detection of recurrent urothelial carcinoma. Cancer 108:60–65. https://doi.org/10.1002/cncr.21712 CrossRefPubMed

29.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R (2008) Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179:2164–2169. https://doi.org/10.1016/j.juro.2008.01.105 CrossRefPubMed

30.

Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y (2010) Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 183:62–67. https://doi.org/10.1016/j.juro.2009.08.157 CrossRefPubMed

31.

32.

Kim PH, Sukhu R, Cordon BH, Sfakianos JP, Sjoberg DD, Hakimi AA et al (2014) Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int 114:354–359. https://doi.org/10.1111/bju.12516 (n/a-n/a) CrossRefPubMedPubMedCentral

33.

Gayed BA, Seideman C, Lotan Y (2013) Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol 190:1181–1186. https://doi.org/10.1016/j.juro.2013.03.117 CrossRefPubMed

34.

Kavalieris L, O’Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E et al (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 197:1419–1426. https://doi.org/10.1016/j.juro.2016.12.010 CrossRefPubMed

35.

Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W et al (2018) Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int 121:29–37. https://doi.org/10.1111/bju.14019 CrossRefPubMed

36.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh J-T, Sagalowsky AI et al (2006) Soluble fas—a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106:1701–1707. https://doi.org/10.1002/cncr.21795 CrossRefPubMed

37.

Yang H, Li H, Wang Z, Gao J, Guo Y (2013) Is urinary soluble fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study. Urol Int 91:456–461. https://doi.org/10.1159/000350752 CrossRefPubMed

38.

Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A, Hennenlotter J et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57:86–94. https://doi.org/10.1016/j.eururo.2009.03.057 CrossRefPubMed

39.

Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626–630. https://doi.org/10.1097/01.ju.0000107826.78479.90 CrossRefPubMed

40.

Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109:1106–1113. https://doi.org/10.1002/cncr.22521 CrossRefPubMed

41.

Brems-Eskildsen AS, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F et al (2010) Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 10:646. https://doi.org/10.1186/1471-2407-10-646 CrossRefPubMedPubMedCentral

42.

Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Diez Gil, de Medina S, Van Rhijn B et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955–1959. https://doi.org/10.1016/S0002-9440(10)64665-2 CrossRefPubMedPubMedCentral

43.

van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265–1268PubMed

44.

Zuiverloon TCM, van der Aa MNM, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH et al (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16:3011–3018. https://doi.org/10.1158/1078-0432.CCR-09-3013 CrossRefPubMed

45.

Su S-F, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S et al (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978–1989. https://doi.org/10.1158/1078-0432.CCR-13-2637 CrossRefPubMed

46.

Ho C-L, Tzai T-S, Chen J-C, Tsai H-W, Cheng H-L, Eisenberger CF et al (2008) the molecular signature for urothelial carcinoma of the upper urinary tract. J Urol 179:1155–1159. https://doi.org/10.1016/j.juro.2007.10.026 CrossRefPubMed

47.

Maldonado L, Brait M, Michailidi C, Munari E, Driscoll T, Schultz L et al (2014) An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget 5:5218–5233. https://doi.org/10.18632/oncotarget.2129 CrossRefPubMedPubMedCentral

48.

Abern MR, Owusu R, Inman BA (2014) Clinical performance and utility of a DNA methylation urine test for bladder cancer11This study was funded, in part, by MDxHealth (formerly OncoMethlyome sciences). Urol Oncol Semin Orig Investig 32:51.e21–51.e26. https://doi.org/10.1016/j.urolonc.2013.08.003 CrossRef

49.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL et al (2017) FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol 197:1410–1418. https://doi.org/10.1016/j.juro.2016.12.096 CrossRefPubMed

50.

Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L et al (2013) A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin Cancer Res 19:4760–4769. https://doi.org/10.1158/1078-0432.CCR-12-3276 CrossRefPubMed

51.

Roperch J-P, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I et al (2016) Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer 16:704. https://doi.org/10.1186/s12885-016-2748-5 CrossRefPubMedPubMedCentral

52.

Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK et al (2017) Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumor Biol 39:101042831769755. https://doi.org/10.1177/1010428317697552 CrossRef

53.

van der Aa MNM, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA et al (2009) Microsatellite Analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study [cost-effectiveness of follow-up of urinary bladder cancer trial (CEFUB)]. Eur Urol 55:659–668. https://doi.org/10.1016/j.eururo.2008.05.001 CrossRefPubMed

54.

Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2006) Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12:7369–7373. https://doi.org/10.1158/1078-0432.CCR-06-1472 CrossRefPubMed

55.

Kojima T, Kawai K, Miyazaki J, Nishiyama H (2017) Biomarkers for precision medicine in bladder cancer. Int J Clin Oncol 22:207–213. https://doi.org/10.1007/s10147-016-1068-8 CrossRefPubMed

56.

Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11:153–162. https://doi.org/10.1038/nrurol.2014.15 CrossRefPubMed

57.

Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer 124:2899–2904. https://doi.org/10.1002/ijc.24258 CrossRefPubMed

58.

Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL et al (2016) Novel fluorescence in situ hybridization-based definition of Bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int 117:754–760. https://doi.org/10.1111/bju.13186 CrossRefPubMed

59.

Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R et al (2016) Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guérin. Eur Urol 69:197–200. https://doi.org/10.1016/j.eururo.2015.06.023 CrossRefPubMed

60.

Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical Bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167:364–367CrossRefPubMed

61.

Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S et al (2003) Urinary interleukin-2 may predict clinical outcome of intravesical Bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52:481–486. https://doi.org/10.1007/s00262-003-0384-9 CrossRefPubMed

62.

de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477–482CrossRefPubMed

63.

Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with Bacillus Calmette-Guerin. J Urol 164:2129–2133CrossRefPubMed

64.

Sagnak L, Ersoy H, Ozok U, Senturk B, Ercil H, Bahar G et al (2009) Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction Bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer 7:E16–E23. https://doi.org/10.3816/CGC.2009.n.016 CrossRefPubMed

65.

Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG et al (2012) Prediction of response to Bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med 4:459–464. https://doi.org/10.3892/etm.2012.634 CrossRefPubMedPubMedCentral

66.

Aguilera Tubet C, Gutiérrez Baños JL, Antolín Juárez F, Rebollo Rodrigo MH, Portillo Martín JA, Ruiz Izquierdo F et al (2005) Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma. Actas Urol Esp 29:252–256CrossRefPubMed

67.

Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V et al (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299. https://doi.org/10.1001/jama.295.3.299 CrossRefPubMed

68.

Kumar A, Kumar R, Gupta NP (2006) Comparison of NMP22 bladder chek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 36:172–175. https://doi.org/10.1093/jjco/hyi244 CrossRefPubMed

69.

Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E (2008) The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer. Arch Esp Urol 61:377–384PubMed

70.

Gupta NP, Sharma N, Kumar R (2009) Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 73:592–596. https://doi.org/10.1016/j.urology.2008.04.051 CrossRefPubMed

71.

Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM (2010) Role of NMP22 bladder check test in early detection of bladder cancer with recurrence. Asian Pac J Cancer Prev 11:1279–1282PubMed

72.

Choi HS, Lee SI, Kim DJ, Jeong TY (2010) Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer. Korean J Urol 51:88. https://doi.org/10.4111/kju.2010.51.2.88 CrossRefPubMedPubMedCentral

73.

Hwang EC, Choi HS, Jung S Il, Kwon DD, Park K, Ryu SB (2011) Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology 77:154–159. https://doi.org/10.1016/j.urology.2010.04.059 CrossRefPubMed

74.

Coskuner E, Cevik I, Ozkan A, Dillioglugil O, Akdas A (2012) In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. Int Urol Nephrol 44:793–798. https://doi.org/10.1007/s11255-012-0144-x CrossRefPubMed

75.

Önal B, Han Ü, Yilmaz S, Köybasioglu F, Altuğ U (2015) The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer-institutional experience and review. Diagn Cytopathol 43:307–314. https://doi.org/10.1002/dc.23239 CrossRefPubMed

76.

Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I (1998) Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52:793–796CrossRefPubMed

77.

Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA (1998) Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 33:387–391CrossRefPubMed

78.

Serretta V, Pomara G, Rizzo I, Esposito E (2000) Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur Urol 38:419–425 (doi:20318) CrossRefPubMed

79.

Chahal R, Darshane A, Browning AJ, Sundaram SK (2001) Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 40:415–420 (discussion 421) CrossRefPubMed

80.

Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C (2001) Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 166:470–475CrossRefPubMed

81.

Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T et al (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45:304–313. https://doi.org/10.1016/j.eururo.2003.10.020 CrossRefPubMed

82.

Lahme S, Bichler K-H, Feil G, Zumbrägel A, Götz T (2003) Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer. Adv Exp Med Biol 539:111–119PubMed

83.

Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF (2006) Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Ann Clin Lab Sci 36:31–38PubMed

84.

Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD (2008) The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int 102:297–300. https://doi.org/10.1111/j.1464-410X.2008.07789.x CrossRefPubMed

85.

Mansoor I, Calam RR, Al-Khafaji B (2008) Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 30:25–32PubMed

86.

Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A (2009) Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 43:461–466. https://doi.org/10.3109/00365590903296837 CrossRefPubMed

87.

Dogan C, Pelit ES, Yildirim A, Ebru Zemheri I, Canakci C, Kaan Başok E et al (2014) The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up. Türk Üroloji Dergisi/Turkish J Urol 39:137–142. https://doi.org/10.5152/tud.2013.029 CrossRef

88.

Ianari A, Sternberg CN, Rossetti A, Van Rijn A, Deidda A, Giannarelli D et al (1997) Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology 49:786–789. https://doi.org/10.1016/S0090-4295(97)00081-2 CrossRefPubMed

89.

Leyh H, Mazeman E (1997) Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 32:425–428PubMed

90.

Kirollos MM (1997) The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder tumour antigen study group. Br J Urol 79:362–366CrossRef

91.

Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J et al (1997) Improved detection of recurrent bladder cancer using the bard BTA stat test. Urology 50:349–353CrossRefPubMed

92.

Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L et al (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168:1950–1954. https://doi.org/10.1097/01.ju.0000034254.89258.8e CrossRefPubMed

93.

Gutiérrez Baños JL, Martín García B, de Diego Rodríguez E, Hernández Rodríguez R, Portillo Martín JA, Correas Gómez MA et al (1999) The BTA stat test in the follow-up for bladder cancer. Arch Esp Urol 52:856–861PubMed

94.

Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT et al (2002) Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma. Arch Esp Urol 55:41–49 (n.d.) PubMed

95.

Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA (2001) Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58:367–371CrossRefPubMed

96.

Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P et al (2003) Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169:921–924. https://doi.org/10.1097/01.ju.0000048983.83079.4c CrossRefPubMed

97.

Têtu B, Tiguert R, Harel F, Fradet Y (2005) ImmunoCyt/uCyt + ™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 18:83–89. https://doi.org/10.1038/modpathol.3800262 CrossRefPubMed

98.

Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 174:1238–1241CrossRefPubMed

99.

Lodde M, Mian C, Comploj E, Palermo S, Longhi E, Marberger M et al (2006) uCyt + test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67:950–954. https://doi.org/10.1016/j.urology.2005.11.057 CrossRefPubMed

100.

Sullivan PS, Nooraie F, Sanchez H, Hirschowitz S, Levin M, Rao PN et al (2009) Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma. Cancer Cytopathol 117:167–173. https://doi.org/10.1002/cncy.20026 CrossRef

101.

Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED (2004) The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol Semin Orig Investig 22:16–19. https://doi.org/10.1016/S1078-1439(03)00098-X CrossRef

102.

Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F et al (2004) Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 63:472–475. https://doi.org/10.1016/j.urology.2003.10.020 CrossRefPubMed

103.

Kipp B, Karnes R, Brankley S, Harwood A, Pankratz V, Sebo T et al (2005) Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173:401–404. https://doi.org/10.1097/01.ju.0000149825.83180.a4 CrossRefPubMed

104.

Bergman J, Reznichek RC, Rajfer J (2007) Surveillance of patients with bladder carcinoma using fluorescent in situ hybridization on bladder washings. BJU Int 0:070915222359021. https://doi.org/10.1111/j.1464-410x.2007.07183.x CrossRef

105.

Moonen PMJ, Merkx GFM, Peelen P, Karthaus HFM, Smeets DFCM, Witjes JA (2007) UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51:1275–1280. https://doi.org/10.1016/j.eururo.2006.10.044 (discussion 1280) CrossRefPubMed

106.

Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS et al (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology. Am J Clin Pathol 127:295–301. https://doi.org/10.1309/ADJL7E810U1H42BJ CrossRefPubMed

107.

Gudjónsson S, Isfoss BL, Hansson K, Domanski A-M, Warenholt J, Soller W et al (2008) The value of the UroVysion® assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54:402–408. https://doi.org/10.1016/j.eururo.2007.11.051 CrossRefPubMed

108.

Karnwal A, Venegas R, Shuch B, Bassett J, Rajfer J, Reznichek R (2010) The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol 17:5077–5081PubMed

109.

Fritsche H-M, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W et al (2010) Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 134:597–603. https://doi.org/10.1309/AJCPKKWBDSAOZ4RW CrossRefPubMed

110.

Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y (2012) Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol Semin Orig Investig 30:273–277. https://doi.org/10.1016/j.urolonc.2010.02.012 CrossRef

Title: An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
Authors: Francesco Soria
Michael J. Droller
Yair Lotan
Paolo Gontero
David D’Andrea
Kilian M. Gust
Morgan Rouprêt
Marek Babjuk
Joan Palou
Shahrokh F. Shariat
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2380-x

2024 ASCO Annual Meeting

Springer Medicine

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

Abstract

Objectives

Methods and materials

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objectives

Methods and materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2018

Medical impulsive therapy (MIT): the impact of 1 week of preoperative tamsulosin on deployment of 16-French ureteral access sheaths without preoperative ureteral stent placement

Patients with disorders of sex development and proximal hypospadias are at high risk for reoperation

Letter to the editor: considering the effects of deep neuromuscular blockade on endoscopic surgical conditions during transurethral resection of a bladder tumor (TURB)

Letter to the Editor regarding the article “A contemporary lower pole approach for complete staghorn calculi: outcomes and efficacy”

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management